Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products.
Undervalued with adequate balance sheet.
Share Price & News
How has Lexicon Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: LXRX's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: LXRX underperformed the US Biotechs industry which returned 6.1% over the past year.
Return vs Market: LXRX underperformed the US Market which returned -6.8% over the past year.
Price Volatility Vs. Market
How volatile is Lexicon Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StNeed To Know: The Consensus Just Cut Its Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Estimates For 2020
1 month ago | Simply Wall StDoes Lexicon Pharmaceuticals (NASDAQ:LXRX) Have A Healthy Balance Sheet?
2 months ago | Simply Wall StHow Much Did Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) CEO Pocket Last Year?
Is Lexicon Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: LXRX ($1.88) is trading below our estimate of fair value ($16.54)
Significantly Below Fair Value: LXRX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: LXRX is good value based on its PE Ratio (1.5x) compared to the Biotechs industry average (16.9x).
PE vs Market: LXRX is good value based on its PE Ratio (1.5x) compared to the US market (13.6x).
Price to Earnings Growth Ratio
PEG Ratio: LXRX's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: LXRX is good value based on its PB Ratio (1.7x) compared to the US Biotechs industry average (2.7x).
How is Lexicon Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LXRX's earnings are forecast to decline over the next 3 years (-8.7% per year).
Earnings vs Market: LXRX's earnings are forecast to decline over the next 3 years (-8.7% per year).
High Growth Earnings: LXRX's earnings are forecast to decline over the next 3 years.
Revenue vs Market: LXRX's revenue is expected to decline over the next 3 years (-10% per year).
High Growth Revenue: LXRX's revenue is forecast to decline over the next 3 years (-10% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: LXRX is forecast to be unprofitable in 3 years.
How has Lexicon Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: LXRX has a high level of non-cash earnings.
Growing Profit Margin: LXRX became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: LXRX has become profitable over the past 5 years, growing earnings by 14% per year.
Accelerating Growth: LXRX has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: LXRX has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (22%).
Return on Equity
High ROE: Whilst LXRX's Return on Equity (111.13%) is outstanding, this metric is skewed due to their high level of debt.
How is Lexicon Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: LXRX's short term assets ($337.8M) exceed its short term liabilities ($65.3M).
Long Term Liabilities: LXRX's short term assets ($337.8M) exceed its long term liabilities ($235.3M).
Debt to Equity History and Analysis
Debt Level: LXRX's debt to equity ratio (209.4%) is considered high.
Reducing Debt: LXRX's debt to equity ratio has increased from 37.9% to 209.4% over the past 5 years.
Debt Coverage: LXRX's debt is well covered by operating cash flow (46.4%).
Interest Coverage: LXRX's interest payments on its debt are well covered by EBIT (9.8x coverage).
What is Lexicon Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate LXRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate LXRX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if LXRX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if LXRX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of LXRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Lonnel Coats (54yo)
Mr. Lonnel Coats has been the Chief Executive Officer and President of Lexicon Pharmaceuticals, Inc., since July 7, 2014. Mr. Coats served as an Executive Vice President, President of Americas Region at Ei ...
CEO Compensation Analysis
Compensation vs Market: Lonnel's total compensation ($USD3.87M) is above average for companies of similar size in the US market ($USD1.43M).
Compensation vs Earnings: Lonnel's compensation has been consistent with company performance over the past year.
|Executive VP of Corporate & Administrative Affairs and CFO||9.92yrs||US$1.61m||0.092% $185.4k|
|Executive Vice President of Commercial Supply Operations||18.75yrs||US$84.55k||0.086% $172.1k|
|Executive VP & Chief Medical Officer||5.17yrs||US$1.46m||0.068% $136.6k|
|Executive Vice President of Research & Development||3.92yrs||US$1.68m||0.051% $102.1k|
|Executive VP & Chief Commercial Officer||3.42yrs||US$1.45m||0.040% $79.9k|
|Consultant & Independent Director||19.17yrs||US$88.76k||0.012% $24.3k|
|Vice President of Finance & Accounting||12.42yrs||US$508.34k||0.052% $105.0k|
|Head of Investor Relations & Corporate Strategy||no data||no data||no data|
|VP, General Counsel & Secretary||no data||no data||0.034% $68.1k|
Experienced Management: LXRX's management team is seasoned and experienced (7.8 years average tenure).
|Consultant & Independent Director||19.17yrs||US$88.76k||0.012% $24.3k|
|Independent Chairman of the Board||8.17yrs||US$118.18k||0.29% $589.2k|
|Independent Director||20.08yrs||US$107.18k||0.049% $98.1k|
|Independent Director||12.67yrs||US$90.96k||0.012% $24.3k|
|Independent Director||12.67yrs||US$84.55k||0.13% $258.1k|
|Independent Director||12.58yrs||US$96.87k||0.012% $24.3k|
|Chairman of Medical Advisory Board & Independent Director||17.08yrs||US$137.05k||0.013% $25.6k|
|Independent Director||15.42yrs||US$105.98k||0.012% $24.3k|
Experienced Board: LXRX's board of directors are seasoned and experienced ( 12.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Lexicon Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Lexicon Pharmaceuticals, Inc.
- Ticker: LXRX
- Exchange: NasdaqGS
- Founded: 1995
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$201.104m
- Shares outstanding: 106.97m
- Website: https://www.lexpharma.com
Number of Employees
- Lexicon Pharmaceuticals, Inc.
- 8800 Technology Forest Place
- The Woodlands
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|LXRX||NasdaqGS (Nasdaq Global Select)||Yes||Common Shares||US||USD||Apr 2000|
|LX31||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Apr 2000|
|LX31||MUN (Boerse Muenchen)||Yes||Common Shares||DE||EUR||Apr 2000|
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase III clinical trials for the treatment of type 1 and type 2 diabetes; LX9211, which is in Phase Ib clinical development for the treatment of neuropathic pain; and LX2761 that is in Phase I clinical development for the treatment of diabetes. The company has strategic collaboration and license agreements with Sanofi; Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/10 07:44|
|End of Day Share Price||2020/04/09 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.